Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Pharmaceuticals, Biotechnology and Diagnostics M&A Agreements Report/Directory 2026: Analyse 2,500+ Deals Signed Since 2021 - Company A-Z, Therapeutic Area, Technology Type, and Industry Segment

globenewswire.com

Pharmaceuticals, Biotechnology and Diagnostics M&A Agreements Report/Directory 2026: Analyse 2,500+ Deals Signed Since 2021 - Company A-Z, Therapeutic Area, Technology Type, and Industry Segment Dublin, March 12, 2026 (GLOBE NEWSWIRE) -- The "Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2021-2026 report provides a comprehensive analysis of acquisition activity across the global life sciences sector. Designed for corporate development, business development, investment, and strategy professionals, the report delivers detailed insight into how companies structure mergers and acquisitions and negotiate the financial terms behind these transactions.

Fully revised and updated, the report analyzes 2,500+ M&A agreements announced between January 2021 and March 2026, offering an extensive view of acquisition activity across pharmaceutical, biotechnology, and diagnostics companies.

Each transaction links to a detailed online deal record and, where available, the original contract documents filed with regulators. By combining comprehensive deal data, financial benchmarking, and contract access, the report provides valuable intelligence for evaluating acquisition opportunities, benchmarking transaction values, and understanding industry consolidation strategies.

Key Benefits

What's Included in the Report

Due Diligence Insights from Real Agreements

Why This Report Matters

Mergers and acquisitions are a critical strategy for pharmaceutical and biotechnology companies seeking to expand pipelines, acquire innovative technologies, and accelerate growth. The life sciences industry experiences significant M&A activity each year as companies pursue strategic acquisitions to strengthen their portfolios and capabilities.

By combining comprehensive acquisition data, transaction benchmarking, and access to real contract documents, this report provides the intelligence needed to evaluate acquisition opportunities, understand industry consolidation trends, and negotiate more effectively.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in M&A dealmaking

2.1. Introduction

2.2. Difference between merger and acquisition deals

2.3. Trends in M&A deals since 2021

2.3.1. M&A dealmaking by year since 2021

2.3.2. M&A dealmaking by industry sector since 2021

2.3.3. M&A dealmaking by therapy area since 2021

2.3.4. M&A dealmaking by most active company since 2021

2.4. Key M&A trends

2.5. Option to acquire the new acquisition?

2.6. When M&A can be useful

2.7. Attributes of M&A deals

2.7.1. M&A as an alternative to IPO

2.8. Partnering deals with M&A component

2.8.1. Partnering as a precursor to M&A

2.8.2. Equity as part of partnering deal

2.8.3. Conversion of partnership to acquisition

2.8.4. But M&A is not always the route followed

2.9. Big pharma mega mergers - are we at the end of the road?

2.9.1. Growth of Johnson & Johnson through M&A

2.9.2. Growth of Novartis through M&A

2.10. Accessing innovation through M&A

2.10.1. Big pharma acquisitions of small companies

2.10.2. Medium and small biopharma - use of M&A

2.10.3. Using M&A to build a company

2.10.4. Emergence of biotech-biotech mergers

2.11. The emerging role of private equity in M&A

2.12. Implementing M&A transactions

2.13. Joint ventures as alternative to M&A

2.14. The future of M&A in biopharma

Chapter 3 - Overview of M&A deal structure

3.1. Introduction

3.2. Pure versus multi-component acquisition deals

3.3. Pure M&A agreement structure

3.4. Acquisition as part of a wider alliance agreement

3.5. Merger agreements

Chapter 4 - Leading M&A deals

4.1. Introduction

4.2. Top M&A deals by value

Chapter 5 - Top 25 most active M&A dealmakers

5.1. Introduction

5.2. Top 25 most active M&A dealmakers

Chapter 6 - M&A contract directory since 2021

6.1. Introduction

6.2. M&A deals with contracts since 2021

For more information about this report visit https://www.researchandmarkets.com/r/ss2g8c

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.